Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Actively personalized vaccination trial for newly diagnosed glioblastoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Genome-wide cell-free DNA fragmentation in patients with cancer

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  2. Tracing the origin of adult intestinal stem cells

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  3. Rising rural body-mass index is the main driver of the global obesity epidemic in adults

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  4. Exome sequencing of 20,791 cases of type 2 diabetes and 24,440 controls

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. The landscape of genomic alterations across childhood cancers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Inflammation induced PD-L1-specific T cells

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Expression and function of Kv1.3 channel in malignant T cells in Sézary syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Norbert Hilf
  • Sabrina Kuttruff-Coqui
  • Katrin Frenzel
  • Valesca Bukur
  • Stefan Stevanović
  • Cécile Gouttefangeas
  • Michael Platten
  • Ghazaleh Tabatabai
  • Valerie Dutoit
  • Sjoerd H van der Burg
  • Per Thor Straten
  • Francisco Martínez-Ricarte
  • Berta Ponsati
  • Hideho Okada
  • Ulrik Lassen
  • Arie Admon
  • Christian H Ottensmeier
  • Alexander Ulges
  • Sebastian Kreiter
  • Andreas von Deimling
  • Marco Skardelly
  • Denis Migliorini
  • Judith R Kroep
  • Manja Idorn
  • Jordi Rodon
  • Jordi Piró
  • Hans S Poulsen
  • Bracha Shraibman
  • Katy McCann
  • Regina Mendrzyk
  • Martin Löwer
  • Monika Stieglbauer
  • Cedrik M Britten
  • David Capper
  • Marij J P Welters
  • Juan Sahuquillo
  • Katharina Kiesel
  • Evelyna Derhovanessian
  • Elisa Rusch
  • Lukas Bunse
  • Colette Song
  • Sandra Heesch
  • Claudia Wagner
  • Alexandra Kemmer-Brück
  • Jörg Ludwig
  • John C Castle
  • Oliver Schoor
  • Arbel D Tadmor
  • Edward Green
  • Jens Fritsche
  • Miriam Meyer
  • Nina Pawlowski
  • Sonja Dorner
  • Franziska Hoffgaard
  • Bernhard Rössler
  • Dominik Maurer
  • Toni Weinschenk
  • Carsten Reinhardt
  • Christoph Huber
  • Hans-Georg Rammensee
  • Harpreet Singh-Jasuja
  • Ugur Sahin
  • Pierre-Yves Dietrich
  • Wolfgang Wick
Vis graf over relationer

Patients with glioblastoma currently do not sufficiently benefit from recent breakthroughs in cancer treatment that use checkpoint inhibitors1,2. For treatments using checkpoint inhibitors to be successful, a high mutational load and responses to neoepitopes are thought to be essential3. There is limited intratumoural infiltration of immune cells4 in glioblastoma and these tumours contain only 30-50 non-synonymous mutations5. Exploitation of the full repertoire of tumour antigens-that is, both unmutated antigens and neoepitopes-may offer more effective immunotherapies, especially for tumours with a low mutational load. Here, in the phase I trial GAPVAC-101 of the Glioma Actively Personalized Vaccine Consortium (GAPVAC), we integrated highly individualized vaccinations with both types of tumour antigens into standard care to optimally exploit the limited target space for patients with newly diagnosed glioblastoma. Fifteen patients with glioblastomas positive for human leukocyte antigen (HLA)-A*02:01 or HLA-A*24:02 were treated with a vaccine (APVAC1) derived from a premanufactured library of unmutated antigens followed by treatment with APVAC2, which preferentially targeted neoepitopes. Personalization was based on mutations and analyses of the transcriptomes and immunopeptidomes of the individual tumours. The GAPVAC approach was feasible and vaccines that had poly-ICLC (polyriboinosinic-polyribocytidylic acid-poly-L-lysine carboxymethylcellulose) and granulocyte-macrophage colony-stimulating factor as adjuvants displayed favourable safety and strong immunogenicity. Unmutated APVAC1 antigens elicited sustained responses of central memory CD8+ T cells. APVAC2 induced predominantly CD4+ T cell responses of T helper 1 type against predicted neoepitopes.

OriginalsprogEngelsk
TidsskriftNature
Vol/bind565
Udgave nummer7738
Sider (fra-til)240-245
Antal sider6
ISSN0028-0836
DOI
StatusUdgivet - jan. 2019

ID: 56272044